Hookipa Biotech, a startup biotech company specialized in developing new generation vaccines. Founded in July 2011, in Austria, Hookipa Biotech has developed a proprietary technology platform, VaxwaveTM, dedicated to genetic vaccines for the prophylactic and therapeutic treatment of viral diseases. VaxwaveTM introduces a new approach to vaccination by providing long lasting and potent stimulation of both cellular and humoral immunity; the platform has been validated in different disease models. The company will use the Series A funds to advance its lead product HB101 through pre-clinical development and a Phase I proof of concept study, and to further industrialize and validate the VaxwaveTM technology.
Dr. Monath has devoted his nearly 30-year career to the fight against infectious disease through his work in the military, corporate, academic and investment sectors. In addition to his role at PaxVax, Dr. Monath is a Partner in the Pandemic and Biodefense Fund at Kleiner Perkins Caufield & Byers. He is also Adjunct Professor at Harvard School of Public Health. From 1992 to 2006, Dr. Monath was Chief Scientific Officer and Executive Director at Acambis, a publicly traded biopharmaceutical company, where he pioneered the development of ChimeriVax vaccines against dengue, West Nile, Japanese encephalitis, as well as vaccines against yellow fever, Clostridium difficile, Helicobacter pylori and smallpox. In 1992, Dr. Monath retired as a U.S. Army colonel following 24 years in the uniformed services.
Chief Scientific Officer at Hookipa Biotech